BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31187275)

  • 1. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
    Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
    J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.
    Gordon D; Young LR; Reddy S; Bergman C; Young JD
    J Hosp Infect; 2016 Feb; 92(2):173-7. PubMed ID: 26616410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
    Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
    Freedberg DE; Salmasian H; Friedman C; Abrams JA
    Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.
    Oshima T; Wu L; Li M; Fukui H; Watari J; Miwa H
    J Gastroenterol; 2018 Jan; 53(1):84-94. PubMed ID: 28744822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do the types and routes of proton pump inhibitor treatments affect
    Lee P; Fike D; Yang H; Hall RG; Pass S; Alvarez CA
    Expert Rev Clin Pharmacol; 2021 Mar; 14(3):399-404. PubMed ID: 33576287
    [No Abstract]   [Full Text] [Related]  

  • 7. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
    Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
    Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.
    Barletta JF; Sclar DA
    Crit Care; 2014 Dec; 18(6):714. PubMed ID: 25540023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
    Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
    Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.
    McDonald EG; Milligan J; Frenette C; Lee TC
    JAMA Intern Med; 2015 May; 175(5):784-91. PubMed ID: 25730198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
    Stevens V; Dumyati G; Brown J; Wijngaarden E
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
    Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
    Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.
    Trifan A; Stanciu C; Girleanu I; Stoica OC; Singeap AM; Maxim R; Chiriac SA; Ciobica A; Boiculese L
    World J Gastroenterol; 2017 Sep; 23(35):6500-6515. PubMed ID: 29085200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.
    Dalton BR; Lye-Maccannell T; Henderson EA; Maccannell DR; Louie TJ
    Aliment Pharmacol Ther; 2009 Mar; 29(6):626-34. PubMed ID: 19183143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients.
    Ro Y; Eun CS; Kim HS; Kim JY; Byun YJ; Yoo KS; Han DS
    Gut Liver; 2016 Jul; 10(4):581-6. PubMed ID: 27021503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
    Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
    World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics.
    Lewis PO; Lundberg TS; Tharp JL; Runnels CW
    Ann Pharmacother; 2017 Oct; 51(10):848-854. PubMed ID: 28821215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis.
    Deshpande A; Pant C; Pasupuleti V; Rolston DD; Jain A; Deshpande N; Thota P; Sferra TJ; Hernandez AV
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):225-33. PubMed ID: 22019794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.
    Freedberg DE; Lamousé-Smith ES; Lightdale JR; Jin Z; Yang YX; Abrams JA
    Clin Infect Dis; 2015 Sep; 61(6):912-7. PubMed ID: 26060292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of Clostridium difficile infection (CDI) in a community hospital.
    Daniel A; Rapose A
    J Infect Public Health; 2015; 8(2):155-60. PubMed ID: 25301221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.